PRDX1-IN-1
Based on 2 publication(s) in Google Scholar
PRDX1-IN-1 is a selective inhibtor of PRDX1 with an IC50 value of 0.164 μM. PRDX1-IN-1 can be used in researches related to cancer.PRDX1-IN-1 promots intracellular ROS accumulation, and inhibits the proliferation, invasion and migration of cancer cells besides inducing apoptosis. PRDX1-IN-1 could be used in cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.04%
- CAS. Nr.: 2996096-63-8
- Formel: C46H55N3O4
- Molecular Weight:713.95
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) PRDX1-IN-1
More
Biologische Aktivität
IC50:0.164μM(potent peroxiredoxin 1,PRDX1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.92 μM
Compound: 7e
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37499289] |
| MDA-MB-231 | IC50 |
2.67 μM
Compound: 7e
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37499289] |
| NCI-H1975 | IC50 |
1.99 μM
Compound: 7e
|
Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37499289] |
| SK-HEP1 | IC50 |
2.42 μM
Compound: 7e
|
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37499289] |
PRDX1-IN-1 inhibites the proliferation activities of the human lung cancer cells A549, lung cancer cell lines (LTEP-a-2 and H1975), human breast cancer cell line (MDA-MB-231), human hepatoma cell line (SK-Hep-1) with the IC50 values of 1.92 μM, 2.93 μM, 1.99 μM, 2.67 μM, 2.42μM, respectively[1].
PRDX1-IN-1 (compound 7e)(2 μM or 4 μM, 24 h) promotes intracellular ROS accumulation, and inhibits the invasion and migration of human lung cancer cells A549[1].
PRDX1-IN-1 (2 μM or 4 μM, 24 h) induces the apoptosis of A549 cells[1].
PRDX1-IN-1 (2 μM or 4 μM, 6 h) suppresses the key signaling pathways (AKT and ERK) and promotes the expression of apoptosis-related proteins (cleaved caspase-3/8 and cleaved PARP) in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:lung cancer cell lines (LTEP-a-2 and H1975), human breast cancer cell line (MDA-MB-231), human hepatoma cell line (SK-Hep-1)
-
Concentration:0.5–10 μM
-
Incubation Time:48 h
-
Result:Inhibited the proliferation activities of cancer cells A549, LTEP-a-2, H1975, MDA-MB-231, SK-Hep-1.
-
Cell Line:human lung cancer cells A549
-
Concentration:2 μM or 4 μM
-
Incubation Time:24 h
-
Result:Increased the ratio of the total number of early (annexin-V+/PI− ) and late (annexin-V+/PI+) apoptotic cells significantly.
-
Cell Line:A549 cell
-
Concentration:2 μM or 4 μM
-
Incubation Time:6 h
-
Result:Decreased the phosphorylation levels of PI3K, AKT, C-RAF and ERK.
-
Cell Line:A549 cell
-
Concentration:2 μM or 4 μM
-
Incubation Time:24 - 48 h
-
Result:Inhibted the cell matrigel and invasion.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J male mice injected with Lewis cell (lung cancer)[1]
-
Dosage:0.5 or 1 mg/kg
-
Administration:intraperitoneal injection (i.p.), every day for 19 days.
-
Result:Inhibited tumor growth, with the tumor growth inhibition (TGI) values of 77.47% and 69.89% in the groups of 1 mg/kg and 0.5 mg/kg, respectively.
Induced the changes in morphological characteristics of tumor cells, including cell agglutination, contraction, and nuclear chromatin marginalization.
Chemical Information
-
CAS. Nr. 2996096-63-8
-
Appearance Solid
-
Molecular Weight 713.95
-
Formel C46H55N3O4
-
Color Light yellow to yellow
-
SMILES
O=C(OC1=C(C)C2=CC=C([C@](CC[C@]3(C)[C@@]4([H])C[C@@](C(NCC5=C(C)N=C(C)C(C)=N5)=O)(C)CC3)(C)[C@@]4(C)CC6)[C@]6(C)C2=CC1=O)/C=C/C7=CC=CC=C7
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Free Radic Biol Med
Peroxiredoxin-1 aggravates hypoxia-induced renal injury by promoting inflammation through the TLR4/MAPK/NF-κB signaling pathway. [Abstract]2025 Aug 16:236:176-187. PMID: 40398686 -
Exp Cell Res
Exosomes derived from diabetic microenvironment-preconditioned mesenchymal stem cells ameliorate nonalcoholic fatty liver disease and inhibit pyroptosis of hepatocytes. [Abstract]2024 Nov 7;443(2):114325. PMID: 39521106
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (140.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (3.50 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4007 mL | 7.0033 mL | 14.0066 mL | 35.0165 mL |
| 5 mM | 0.2801 mL | 1.4007 mL | 2.8013 mL | 7.0033 mL | |
| 10 mM | 0.1401 mL | 0.7003 mL | 1.4007 mL | 3.5016 mL | |
| 15 mM | 0.0934 mL | 0.4669 mL | 0.9338 mL | 2.3344 mL | |
| 20 mM | 0.0700 mL | 0.3502 mL | 0.7003 mL | 1.7508 mL | |
| 25 mM | 0.0560 mL | 0.2801 mL | 0.5603 mL | 1.4007 mL | |
| 30 mM | 0.0467 mL | 0.2334 mL | 0.4669 mL | 1.1672 mL | |
| 40 mM | 0.0350 mL | 0.1751 mL | 0.3502 mL | 0.8754 mL | |
| 50 mM | 0.0280 mL | 0.1401 mL | 0.2801 mL | 0.7003 mL | |
| 60 mM | 0.0233 mL | 0.1167 mL | 0.2334 mL | 0.5836 mL | |
| 80 mM | 0.0175 mL | 0.0875 mL | 0.1751 mL | 0.4377 mL | |
| 100 mM | 0.0140 mL | 0.0700 mL | 0.1401 mL | 0.3502 mL |